GlassScriptPhysician profile
Nydia E Providence
NPI 1861552333
$1,650.84
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $44.55 · 2021: $189 · 2022: $36.51 · 2023: $542 · 2024: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $244.92 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.31 | 2019-2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $161.24 | 2019-2021 | |
| Pfizer INC. | $158.31 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $130.46 | 2019 | |
| Merck Sharp & Dohme LLC | $122.85 | 2019-2023 | Verquvo |
| Lilly USA, LLC | $122.26 | 2023-2024 | Mounjaro, Taltz, Olumiant |
| Glaxosmithkline, LLC. | $113.60 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $76.48 | 2023-2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $58.99 | 2019 | |
| Astellas Pharma US INC | $47.35 | 2019 | |
| Boston Scientific Corporation | $44.92 | 2022-2023 | Watchman Access System |
| Intra-Sana Laboratories | $40.64 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Otsuka America Pharmaceutical, INC. | $40.24 | 2024 | Nuedexta |
| Allergan, INC. | $35.74 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $28.47 | 2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $23.40 | 2021 | |
| Amarin Pharma, INC. | $22.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nydia Providence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.